You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCapecitabine
Accession NumberDB01101  (APRD00203)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionCapecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Structure
Thumb
Synonyms
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
Capecitabinum
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Xeloda
External IDs R340
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-capecitabineTablet150 mgOralAccord Healthcare Limited2014-09-19Not applicableCanada
Ach-capecitabineTablet500 mgOralAccord Healthcare Limited2014-09-19Not applicableCanada
Sandoz CapecitabineTablet150 mgOralSandoz Canada Incorporated2014-07-23Not applicableCanada
Sandoz CapecitabineTablet500 mgOralSandoz Canada Incorporated2014-07-23Not applicableCanada
Taro-capecitabineTablet500 mgOralTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada
Taro-capecitabineTablet150 mgOralTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada
Teva-capecitabineTablet500 mgOralTeva2013-08-19Not applicableCanada
Teva-capecitabineTablet150 mgOralTeva2013-08-19Not applicableCanada
XelodaTablet, film coated500 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
XelodaTablet, film coated150 mg/1OralPhysicians Total Care, Inc.2005-02-20Not applicableUs
XelodaTablet, film coated500 mg/1OralPhysicians Total Care, Inc.2005-06-28Not applicableUs
XelodaTablet, film coated150 mg/1OralGenentech, Inc.1998-04-30Not applicableUs
XelodaTablet150 mgOralHoffmann La Roche1998-09-10Not applicableCanada
XelodaTablet, film coated500 mg/1OralGenentech, Inc.1998-04-30Not applicableUs
XelodaTablet500 mgOralHoffmann La Roche1998-09-10Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-capecitabineTablet150 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-capecitabineTablet500 mgOralApotex CorporationNot applicableNot applicableCanada
CapecitabineTablet, film coated150 mg/1OralShilpa Medicare Limited2016-12-31Not applicableUs
CapecitabineTablet, film coated500 mg/1OralKaiser Foundations Hospitals2014-05-14Not applicableUs
CapecitabineTablet, film coated500 mg/1OralAmerincan Health Packaging2015-10-01Not applicableUs
CapecitabineTablet150 mg/1OralAmneal Pharmaceuticals2017-03-10Not applicableUs
CapecitabineTablet, film coated150 mg/1OralMylan Pharmaceuticals2014-08-08Not applicableUs
CapecitabineTablet, film coated500 mg/1OralKaiser Foundations Hospitals2015-12-02Not applicableUs
CapecitabineTablet, film coated500 mg/1OralShilpa Medicare Limited2016-12-31Not applicableUs
CapecitabineTablet500 mg/1OralAmneal Pharmaceuticals2017-03-10Not applicableUs
CapecitabineTablet, film coated500 mg/1OralMylan Pharmaceuticals2014-08-08Not applicableUs
CapecitabineTablet, film coated150 mg/1OralNorth Star Rx Llc2015-11-01Not applicableUs
CapecitabineTablet, film coated150 mg/1OralTeva2014-03-07Not applicableUs
CapecitabineTablet500 mg/1OralAv Kare, Inc.2017-04-12Not applicableUs
CapecitabineTablet, film coated500 mg/1OralMylan Institutional2014-01-21Not applicableUs
CapecitabineTablet, film coated500 mg/1OralNorth Star Rx Llc2015-11-01Not applicableUs
CapecitabineTablet, film coated150 mg/1OralAccord Healthcare Limited2015-05-22Not applicableUs
CapecitabineTablet, film coated500 mg/1OralTeva2014-03-07Not applicableUs
CapecitabineTablet, film coated150 mg/1OralWest Ward Pharmaceutical2016-07-15Not applicableUs
CapecitabineTablet, film coated150 mg/1OralAv Kare, Inc.2015-03-20Not applicableUs
CapecitabineTablet, film coated500 mg/1OralAccord Healthcare Limited2015-05-20Not applicableUs
CapecitabineTablet, film coated150 mg/1OralRising Pharmaceuticals2017-02-01Not applicableUs
CapecitabineTablet, film coated500 mg/1OralWest Ward Pharmaceutical2016-07-15Not applicableUs
CapecitabineTablet, film coated500 mg/1OralAv Kare, Inc.2015-03-20Not applicableUs
CapecitabineTablet, film coated500 mg/1OralRising Pharmaceuticals2017-02-01Not applicableUs
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated300 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated500 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine AccordTablet, film coated150 mgOralAccord Healthcare Limited2012-04-20Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated150 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated500 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine MedacTablet, film coated300 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2012-11-19Not applicableEu
Capecitabine SunTablet, film coated150 mgOralSun Pharmaceutical Industries (Europe) B.V.2013-06-21Not applicableEu
Capecitabine SunTablet, film coated500 mgOralSun Pharmaceutical Industries (Europe) B.V.2013-06-21Not applicableEu
Capecitabine TevaTablet, film coated150 mgOralTeva Pharma B.V.  2012-04-20Not applicableEu
Capecitabine TevaTablet, film coated500 mgOralTeva Pharma B.V.  2012-04-20Not applicableEu
EcansyaTablet, film coated500 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated150 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated300 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated500 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated150 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated300 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated500 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated150 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated300 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated500 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated150 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated300 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated500 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated150 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated300 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated500 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated150 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
EcansyaTablet, film coated300 mgOralKrka, D.D., Novo Mesto  2012-04-20Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII6804DJ8Z9U
CAS number154361-50-9
WeightAverage: 359.3501
Monoisotopic: 359.149263656
Chemical FormulaC15H22FN3O6
InChI KeyGAGWJHPBXLXJQN-UORFTKCHSA-N
InChI
InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
IUPAC Name
pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate
SMILES
CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[[email protected]](C)[C@@H](O)[[email protected]]1O
Pharmacology
IndicationFor the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Structured Indications
PharmacodynamicsCapecitabine is a fluoropyrimidine carbamate with antineoplastic activity indicated for the treatment of metastatic breast cancer and colon cancer. It is an orally administered systemic prodrug that has little pharmacologic activity until it is converted to fluorouracil by enzymes that are expressed in higher concentrations in many tumors. Fluorouracil it then metabolized both normal and tumor cells to 5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP).
Mechanism of actionCapecitabine is a prodrug that is selectively tumour-activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many tumors compared to normal tissues or plasma. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deaxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, therefore a deficiency of this compound can inhibit cell division. Secondly, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis through the production of fraudulent RNA.
TargetKindPharmacological actionActionsOrganismUniProt ID
Thymidylate synthaseProteinyes
inhibitor
HumanP04818 details
DNANucleotideyes
incorporation into and destabilization
Humannot applicabledetails
RNANucleotideyes
incorporation into and destabilization
Humannot applicabledetails
Related Articles
AbsorptionReadily absorbed through the GI tract (~70%)
Volume of distributionNot Available
Protein binding< 60% (mainly albumin)
Metabolism

Metabolized by thymidine phosphorylase to fluoruracil.

SubstrateEnzymesProduct
Capecitabine
5’-Deoxy-5-fluorouridineDetails
5’-Deoxy-5-fluorouridine
5-fluorouracilDetails
Route of eliminationCapecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Fecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL which represents 57% of the administered dose.About 3% of the administered dose is excreted in urine as unchanged drug.
Half life45-60 minutes for capecitabine and its metabolites.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Capecitabine Metabolism PathwayDrug metabolismSMP00607
Capecitabine Action PathwayDrug actionSMP00469
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeSNP RS IDsAllele nameGenotypeDefining ChangeType(s)DescriptionDetails
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*2A(A;A) or (A;G)G > AADR Directly StudiedAssociated with 5-fluoracil toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*13(C;C) or (A;C)A > CADR Directly StudiedAssociated with 5-fluoracil toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]---(A;A) or (A;T)T > AADR Directly StudiedAssociated with 5-fluoracil toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*4(G;G) or (A:G)G > AADR Directly StudiedAssociated with toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*5(G;G) or (A;G)A > GADR Directly StudiedAssociated with toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*6(A;A) or (A;G)G > AADR Directly StudiedAssociated with 5-fluoracil toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*9A(C;C) or (C;T)T > CADR Directly StudiedAssociated with toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*2A---G > AADR InferredAssociated with 5-fluoracil toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*13---A > CADR InferredAssociated with 5-fluoracil toxicity Details
Dihydropyrimidine dehydrogenase [NADP(+)]------T > AADR InferredAssociated with 5-fluoracil toxicity Details
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Capecitabine.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Capecitabine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Capecitabine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Capecitabine.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Capecitabine.Approved, Vet Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Capecitabine.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Capecitabine.Approved, Illicit, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Capecitabine.Approved, Withdrawn
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Capecitabine.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Capecitabine.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Capecitabine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Capecitabine.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Capecitabine.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Capecitabine.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Capecitabine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Capecitabine.Approved
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Capecitabine.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Capecitabine.Approved
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Capecitabine.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Capecitabine.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Capecitabine.Approved, Investigational
BortezomibThe metabolism of Bortezomib can be decreased when combined with Capecitabine.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Capecitabine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Capecitabine.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Capecitabine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Capecitabine.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Capecitabine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Capecitabine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Capecitabine.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Capecitabine.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Capecitabine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Capecitabine.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Capecitabine.Approved, Investigational
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Capecitabine.Approved
CimetidineThe serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Cimetidine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Capecitabine.Approved
CisaprideThe metabolism of Cisapride can be decreased when combined with Capecitabine.Approved, Investigational, Withdrawn
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Capecitabine.Approved, Nutraceutical
ClozapineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Clozapine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Capecitabine.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Capecitabine.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Capecitabine.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Capecitabine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Capecitabine.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Capecitabine.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Capecitabine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Capecitabine.Approved, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Capecitabine.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Capecitabine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Capecitabine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Capecitabine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Capecitabine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Capecitabine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Capecitabine.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Capecitabine.Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Capecitabine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Capecitabine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Capecitabine.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Capecitabine.Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Capecitabine.Approved, Illicit
EletriptanThe metabolism of Eletriptan can be decreased when combined with Capecitabine.Approved, Investigational
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Capecitabine.Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Capecitabine.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Capecitabine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Capecitabine.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Capecitabine.Withdrawn
EtodolacThe metabolism of Etodolac can be decreased when combined with Capecitabine.Approved, Investigational, Vet Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Capecitabine.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Capecitabine.Approved
FingolimodCapecitabine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Capecitabine.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Capecitabine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Capecitabine.Approved, Illicit
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Capecitabine.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Capecitabine.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Capecitabine.Approved
FormoterolThe metabolism of Formoterol can be decreased when combined with Capecitabine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Capecitabine.Approved
G17DTThe risk or severity of adverse effects can be increased when Capecitabine is combined with G17DT.Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Capecitabine.Investigational
GI-5005The risk or severity of adverse effects can be increased when Capecitabine is combined with GI-5005.Investigational
GimeracilThe serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Gimeracil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Capecitabine.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Capecitabine.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Capecitabine.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Capecitabine.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Capecitabine.Approved, Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Capecitabine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Capecitabine.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Capecitabine.Approved
HistamineThe metabolism of Histamine Phosphate can be decreased when combined with Capecitabine.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Capecitabine.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Capecitabine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Capecitabine.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Capecitabine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Capecitabine.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Capecitabine.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Capecitabine.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Capecitabine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Capecitabine is combined with INGN 225.Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Capecitabine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Capecitabine.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Capecitabine.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Capecitabine.Approved
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Capecitabine.Approved, Vet Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Capecitabine.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Capecitabine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Capecitabine is combined with Leflunomide.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Capecitabine.Approved
LeucovorinThe risk or severity of adverse effects can be increased when Leucovorin is combined with Capecitabine.Approved
LevoleucovorinThe risk or severity of adverse effects can be increased when Levoleucovorin is combined with Capecitabine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Capecitabine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Capecitabine.Approved, Vet Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Capecitabine.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Capecitabine.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Capecitabine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Capecitabine.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Capecitabine.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Capecitabine.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Capecitabine.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Capecitabine.Investigational, Withdrawn
MestranolThe metabolism of Mestranol can be decreased when combined with Capecitabine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Capecitabine.Withdrawn
MethadoneThe metabolism of Methadone can be decreased when combined with Capecitabine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Capecitabine.Approved, Vet Approved
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Capecitabine.Approved
MetronidazoleThe serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Metronidazole.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Capecitabine.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Capecitabine.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Capecitabine.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Capecitabine.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Capecitabine is combined with Natalizumab.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Capecitabine.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Capecitabine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Capecitabine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Capecitabine.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Capecitabine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Capecitabine.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Capecitabine.Experimental
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Capecitabine.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Capecitabine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Capecitabine.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Capecitabine.Approved
OuabainOuabain may decrease the cardiotoxic activities of Capecitabine.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Capecitabine.Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Capecitabine.Approved, Vet Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Capecitabine.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Capecitabine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Capecitabine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Capecitabine.Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Capecitabine.Approved
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Capecitabine.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Capecitabine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Capecitabine.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Capecitabine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Capecitabine.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Capecitabine.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Capecitabine.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Capecitabine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Capecitabine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Capecitabine.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Capecitabine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Capecitabine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Capecitabine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Capecitabine.Approved, Investigational, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Capecitabine.Approved, Illicit
QuinidineThe metabolism of Quinidine can be decreased when combined with Capecitabine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Capecitabine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Capecitabine.Approved
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Capecitabine.Approved, Investigational
RifampicinThe metabolism of Rifampicin can be decreased when combined with Capecitabine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Capecitabine is combined with CDX-110.Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Capecitabine.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Capecitabine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Capecitabine.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Capecitabine.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Capecitabine.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Capecitabine.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Capecitabine.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Capecitabine.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Capecitabine.Approved, Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Capecitabine.Approved
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Capecitabine.Approved, Investigational, Withdrawn
SRP 299The risk or severity of adverse effects can be increased when Capecitabine is combined with SRP 299.Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Capecitabine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Capecitabine.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Capecitabine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Capecitabine.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Capecitabine.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Capecitabine.Approved, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Capecitabine.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Capecitabine.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Capecitabine.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Capecitabine.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Capecitabine.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Capecitabine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Capecitabine.Withdrawn
TestosteroneThe metabolism of Testosterone can be decreased when combined with Capecitabine.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Capecitabine is combined with TG4010.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Capecitabine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Capecitabine.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Capecitabine.Approved, Vet Approved
TofacitinibCapecitabine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Capecitabine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Capecitabine.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Capecitabine.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Capecitabine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Capecitabine.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Capecitabine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Capecitabine.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Capecitabine.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Capecitabine.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Capecitabine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Capecitabine.Withdrawn
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Capecitabine.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Capecitabine.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Capecitabine.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Capecitabine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Capecitabine.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Capecitabine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Capecitabine.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Capecitabine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Capecitabine.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Capecitabine.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Capecitabine.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Capecitabine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Capecitabine.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Capecitabine.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Capecitabine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Capecitabine.Approved, Investigational, Withdrawn
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Capecitabine.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Capecitabine.Approved
Food Interactions
  • Take 12 hours apart, within 30 minutes of the end of breakfast and dinner to reduce nausea.
References
Synthesis Reference

DrugSyn.org

US5472949
General References
  1. Walko CM, Lindley C: Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. [PubMed:15763604 ]
  2. Wagstaff AJ, Ibbotson T, Goa KL: Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63(2):217-36. [PubMed:12515569 ]
  3. Koukourakis GV, Kouloulias V, Koukourakis MJ, Zacharias GA, Zabatis H, Kouvaris J: Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules. 2008 Aug 27;13(8):1897-922. [PubMed:18794792 ]
  4. Twelves C: Vision of the future: capecitabine. Oncologist. 2001;6 Suppl 4:35-9. [PubMed:11585973 ]
  5. Milano G, Ferrero JM, Francois E: Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer. 2004 Aug 16;91(4):613-7. [PubMed:15280932 ]
  6. de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs. 2001;19(1):41-59. [PubMed:11291832 ]
External Links
ATC CodesL01BC06
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (133 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Cancers2
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Carcinoma of the Prostate / Carcinoma, Colorectal / Carcinoma, Pancreatic / Melanoma / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Carcinoma (RCC) / Tumors, Solid1
1Active Not RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Cardio-esophageal Junction of Stomach1
1Active Not RecruitingTreatmentEsophageal Cancers / Neoplasms, Esophageal1
1Active Not RecruitingTreatmentHER2 Positive Metastatic Breast Cancers1
1Active Not RecruitingTreatmentLiver Cancer / Metastatic Cancers1
1Active Not RecruitingTreatmentRectal Adenocarcinoma1
1Active Not RecruitingTreatmentRelapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma1
1Active Not RecruitingTreatmentTumors, Solid1
1CompletedPreventionNeoplasms1
1CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Primary CNS Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / HER2-Negative Breast Cancer / HIV-associated Hodgkin Lymphoma / Intraocular Lymphoma / Male Breast Cancer / Nodal marginal zone B-cell lymphomas / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Breast Cancer / Recurrent Colon Cancer / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Rectal Cancer / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Colon Cancer / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Rectal Cancer / Stage III Small Lymphocytic Lymphoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Breast Cancer / Stage IV Colon Cancer / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Rectal Cancer / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdenocarcinomas / Neoplasms, Pancreatic / Pancreatic Cancers1
1CompletedTreatmentAdults / Tumors, Solid1
1CompletedTreatmentAdvanced Breast Cancer1
1CompletedTreatmentAdvanced Colorectal Cancer / Metastatic Colorectal Cancers / Neoplasms, Colorectal / Responsive to Fluoropyrimidines1
1CompletedTreatmentAdvanced Gastrointestinal Malignancies / Tumors, Solid1
1CompletedTreatmentAdvanced Malignant Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Locally Advanced or Metastatic Breast or Colorectal Cancer1
1CompletedTreatmentAdvanced Solid Tumors / Neoplasms1
1CompletedTreatmentAnal, Colon, and Rectal Cancers / Colon/Rectal Cancer / Neoplasms, Colorectal1
1CompletedTreatmentBiliary Cancer / Malignant Solid Tumours / Pancreatic Cancers1
1CompletedTreatmentBiliary Cancer / Pancreatic Cancers1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentBreast Cancer, Colorectal Cancer1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancer, Advanced / Tumors, Solid1
1CompletedTreatmentCancer, Breast6
1CompletedTreatmentCancer, Breast / Colon Cancer1
1CompletedTreatmentCancer, Breast / Neoplasms / Tumors, Solid1
1CompletedTreatmentCancers2
1CompletedTreatmentCancers / Pancreas1
1CompletedTreatmentCancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCarcinoma of the Appendix / Colorectal Cancers / Small Intestine Cancer1
1CompletedTreatmentColon Cancer1
1CompletedTreatmentColorectal Cancers2
1CompletedTreatmentColorectal Cancers / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentEsophageal Cancers2
1CompletedTreatmentEsophagus Disorders / Squamous Carcinoma of Esophagus1
1CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Gastric Cancers / Liver Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentGastric Cancers2
1CompletedTreatmentGastric cancer stage IV1
1CompletedTreatmentGastric cancer stage IV / Stomach Neoplasms1
1CompletedTreatmentGastrointestinal Tumors / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentGliomas1
1CompletedTreatmentHER-2 Gene Amplification1
1CompletedTreatmentHead and Neck Cancers1
1CompletedTreatmentHepatic cancer metastatic1
1CompletedTreatmentLocally Advanced Breast Cancer (LABC) / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentLocally Advanced Rectal Cancer1
1CompletedTreatmentMetastatic Biliary Cancers / Metastatic Breast Cancer (MBC) / Metastatic Colorectal Cancers / Metastatic Gastric Cancers / Metastatic Oesophageal Cancers / Pancreatic Cancer Metastatic1
1CompletedTreatmentMetastatic Breast Cancer (MBC)2
1CompletedTreatmentMetastatic Breast Cancer (MBC) / Metastatic Colorectal Cancers / Pancreatic Cancers / Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC)1
1CompletedTreatmentMetastatic Breast Cancer or Metastatic Colorectal Cancer1
1CompletedTreatmentMetastatic Colorectal Cancers / Tumors, Solid1
1CompletedTreatmentMetastatic Pancreatic Carcinoma1
1CompletedTreatmentMetastatic or Unresectable Solid Tumor Malignancy1
1CompletedTreatmentNeoplasms2
1CompletedTreatmentNeoplasms, Colorectal1
1CompletedTreatmentNeoplasms, Esophageal1
1CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
1CompletedTreatmentPancreatic Cancers7
1CompletedTreatmentPancreatic Cancers / Periampullary Adenocarcinoma1
1CompletedTreatmentRectal Cancers2
1CompletedTreatmentRectal Neoplasms2
1CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRefractory Malignancy1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentSolid Tumor Cancers1
1CompletedTreatmentStomach Cancer1
1CompletedTreatmentStomach Neoplasms2
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific10
1Not Yet RecruitingTreatmentCancer, Advanced / Malignant Neoplasm of Breast / Malignant Neoplasms of Bone and Articular Cartilage / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract1
1Not Yet RecruitingTreatmentFunctional Pancreatic Neuroendocrine Tumor / Malignant Somatostatinoma / Metastatic Adrenal Gland Pheochromocytoma / Metastatic Carcinoid Tumors / Multiple Endocrine Neoplasia Type 1 / Multiple Endocrine Neoplasia Type 2a / Multiple Endocrine Neoplasia Type 2B / Neuroendocrine Carcinoma of the Skin / Neuroendocrine Neoplasms / Non-Functional Pancreatic Neuroendocrine Tumor / Pancreatic Glucagonoma / Pancreatic Insulinoma / Recurrent Adrenal Cortex Carcinoma / Recurrent Adrenal Gland Pheochromocytoma / Recurrent Merkel Cell Carcinoma / Somatostatin-Producing Neuroendocrine Tumor / Stage III Adrenal Cortex Carcinoma / Stage III Thyroid Gland Medullary Carcinoma / Stage IIIA Merkel Cell Carcinoma / Stage IIIB Merkel Cell Carcinoma / Stage IV Adrenal Cortex Carcinoma / Stage IV Merkel Cell Carcinoma / Stage IVA Thyroid Gland Medullary Carcinoma / Stage IVB Thyroid Gland Medullary Carcinoma / Stage IVC Thyroid Gland Medullary Carcinoma / Thymic Carcinoid Tumor / VIP-Producing Neuroendocrine Tumor / Well Differentiated Adrenal Cortex Carcinoma / Zollinger-Ellison Syndrome1
1RecruitingTreatmentAdvanced or Metastatic Biliary Tract Cancer / Advanced or Metastatic Solid Tumors1
1RecruitingTreatmentBile Duct Carcinoma / Recurrent Pancreatic Carcinoma / Solid Neoplasms / Stage III Pancreatic Cancer / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentCancers / Metastatic Colorectal Cancer (MCRC) / Tumors, Solid1
1RecruitingTreatmentCarcinomas1
1RecruitingTreatmentGlioblastomas1
1RecruitingTreatmentHepatocellular Carcinomas1
1RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1RecruitingTreatmentMetastatic Colorectal Cancers1
1RecruitingTreatmentNeoplasms1
1RecruitingTreatmentPancreatic Cancers2
1RecruitingTreatmentRectal Adenocarcinoma / Rectal Cancers1
1RecruitingTreatmentRectal Cancers2
1RecruitingTreatmentRectal Neoplasms1
1RecruitingTreatmentStage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
1RecruitingTreatmentTumors, Solid3
1TerminatedTreatmentAdenocarcinoma of the Pancreas / Adenocarcinoma of the Stomach / BRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Ovarian Mucinous Cystadenocarcinoma / Recurrent Breast Cancer / Recurrent Colon Cancer / Recurrent Gastric Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pancreatic Cancer / Recurrent Rectal Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Colon Cancer / Stage IV Gastric Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Pancreatic Cancer / Stage IV Rectal Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentAdenocarcinomas / Esophageal Cancers / Neoplasms, Esophageal / Squamous Cell Carcinoma (SCC)1
1TerminatedTreatmentCancer of Liver1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentColorectal Cancers / Gastric Cancers1
1TerminatedTreatmentColorectal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentFailure or Contraindication of Trastuzumab Therapy / First or Second Line Therapy / HER2 Positive / Metastatic Breast Cancer (MBC)1
1TerminatedTreatmentLocally Advanced or Metastatic Breast Cancer1
1TerminatedTreatmentMalignancies1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentNon-Metastatic Adenocarcinoma of the Rectum1
1TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1Unknown StatusTreatmentCancers1
1Unknown StatusTreatmentGastric Carcinoma1
1Unknown StatusTreatmentPancreatic Cancers1
1Unknown StatusTreatmentRectal Cancers1
1Unknown StatusTreatmentTumors, Solid1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Vaginal Cancers1
1WithdrawnTreatmentPancreatic Cancers1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentCentral Nervous System Metastases / HER2-positive Breast Cancer / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2Active Not RecruitingTreatmentColorectal Adenocarcinoma1
1, 2Active Not RecruitingTreatmentGastric Cancers / Histone Deacetylase Inhibitor1
1, 2Active Not RecruitingTreatmentHER2 Positive Metastatic Breast Cancers1
1, 2Active Not RecruitingTreatmentMetastatic Colorectal Cancers2
1, 2Active Not RecruitingTreatmentPancreatic Cancers2
1, 2Active Not RecruitingTreatmentRectal Cancers1
1, 2Active Not RecruitingTreatmentRecurrent Renal Cell Carcinoma / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2CompletedTreatmentAdult Solid Neoplasm / Inflammatory Breast Carcinoma / Male Breast Carcinoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
1, 2CompletedTreatmentBile Duct Neoplasms / Neoplasms, Pancreatic1
1, 2CompletedTreatmentCancer of the Esophagus1
1, 2CompletedTreatmentCancer, Breast5
1, 2CompletedTreatmentCancer, Breast / Cancers1
1, 2CompletedTreatmentCholangiocarcinomas1
1, 2CompletedTreatmentColon/Rectal Cancer / Colon/Rectal Cancer Rectal Cancer / Rectal Cancers1
1, 2CompletedTreatmentColorectal Cancers7
1, 2CompletedTreatmentEsophageal Cancers / Esophagogastric Junction Adenocarcinoma / Gastric Cancers1
1, 2CompletedTreatmentEsophageal Cancers / Extrahepatic Bile Duct Cancer / Gastric Cancers / Head and Neck Cancers / Liver Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentEsophagus Cancer1
1, 2CompletedTreatmentGastric cancer stage IV1
1, 2CompletedTreatmentHepatocellular Carcinomas / Liver Cancer1
1, 2CompletedTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
1, 2CompletedTreatmentMetastatic Gastric Cancers1
1, 2CompletedTreatmentNeoplasm Metastases / Neoplasms, Breast1
1, 2CompletedTreatmentPancreatic Cancer Metastatic1
1, 2CompletedTreatmentPancreatic Cancers1
1, 2CompletedTreatmentStage IV Colorectal Cancer1
1, 2Enrolling by InvitationTreatmentTumors, Solid1
1, 2Not Yet RecruitingTreatmentMetastatic Cancers1
1, 2RecruitingTreatmentAdvanced Gastrointestinal Cancers1
1, 2RecruitingTreatmentBiliary Tract Cancer1
1, 2RecruitingTreatmentCancer of Pancreas / Cancer of the Pancreas / Pancreas Cancer / Pancreatic Cancers1
1, 2RecruitingTreatmentCancer, Advanced / Carcinoma, Colorectal / Endometrial / Non Small Cell Lung Cancer (NSCLC) / Pancreatic Cancers / Renal Cell Cancer / Uterine1
1, 2RecruitingTreatmentCancers1
1, 2RecruitingTreatmentColon Adenocarcinoma / Rectal Adenocarcinoma / Recurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1, 2RecruitingTreatmentColon Cancer / Colorectal Cancers / Rectal Cancers / Tumors, Solid1
1, 2RecruitingTreatmentColorectal Cancers2
1, 2RecruitingTreatmentEsophageal Cancers1
1, 2RecruitingTreatmentGastric Cancers1
1, 2RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
1, 2RecruitingTreatmentNeoplasms, Colorectal / Neoplasms, Gastrointestinal / Neoplasms, Pancreatic / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2RecruitingTreatmentPancreatic Neoplasms (Locally Advanced Non-metastatic)1
1, 2RecruitingTreatmentRectal Cancers2
1, 2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2TerminatedTreatmentAdenocarcinomas / Tumors / Unknown Primary Tumors1
1, 2TerminatedTreatmentAdvanced Breast Cancer (Parts 1 and 2) / Advanced Cholangiocarcinoma (Part 1) / Advanced Colorectal Cancer (Part 1) / Advanced Glioblastoma Multiforme (Part 1) / Advanced Pancreatic Cancer (Part 1)1
1, 2TerminatedTreatmentAdvanced or Metastatic Solid Tumors / Previously Untreated Gastric Cancer1
1, 2TerminatedTreatmentColorectal Cancers1
1, 2TerminatedTreatmentEsophageal Adenocarcinomas / Gastric Adenocarcinoma1
1, 2TerminatedTreatmentEsophageal Cancers / Gastric Cancers / Tumors1
1, 2TerminatedTreatmentGastric Cancers1
1, 2TerminatedTreatmentHER2 + Breast Cancer / Metastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentMetastatic Colorectal Cancers1
1, 2TerminatedTreatmentPancreatic Cancers2
1, 2TerminatedTreatmentStage II Rectal Cancer / Stage III Rectal Cancer1
1, 2TerminatedTreatmentThyroid Cancers / Tumors, Solid1
1, 2Unknown StatusNot AvailableCancer treatment / Neoplasms, Breast1
1, 2Unknown StatusTreatmentAdvanced Malignancies1
1, 2Unknown StatusTreatmentAdvanced Solid Tumors1
1, 2Unknown StatusTreatmentCancer of the Esophagus / Gastric Cardia Carcinoma1
1, 2Unknown StatusTreatmentColorectal Cancers1
1, 2Unknown StatusTreatmentGastric Carcinoma1
1, 2Unknown StatusTreatmentGastric cancer stage IV1
1, 2Unknown StatusTreatmentRectal Cancers1
1, 2WithdrawnTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Stage IV Breast Cancer1
1, 2WithdrawnTreatmentPancreatic Cancers1
1, 2WithdrawnTreatmentRectal Cancers1
2Active Not RecruitingNot AvailableAdenocarcinoma of the Gastro-oesophageal Junction / Metastatic Gastric Cancers1
2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Gastric Cancers1
2Active Not RecruitingTreatmentAdenocarcinomas / Rectal Neoplasms1
2Active Not RecruitingTreatmentAdult Cholangiocarcinoma / Advanced Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma / BCLC Stage D Adult Hepatocellular Carcinoma / Hilar Cholangiocarcinoma / Localized Non-Resectable Adult Liver Carcinoma / Recurrent Adult Liver Carcinoma / Recurrent Childhood Liver Cancer / Recurrent Extrahepatic Bile Duct Carcinoma / Recurrent Gallbladder Carcinoma / Stage II Gallbladder Cancer / Stage III Childhood Hepatocellular Carcinoma / Stage IIIA Gallbladder Cancer / Stage IIIB Gallbladder Cancer / Stage IV Childhood Hepatocellular Carcinoma / Stage IV Distal Bile Duct Cancer / Stage IVA Gallbladder Cancer / Stage IVB Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Carcinoma1
2Active Not RecruitingTreatmentAdvanced Breast Cancer / Cancer, Breast1
2Active Not RecruitingTreatmentAdvanced Colorectal Cancer1
2Active Not RecruitingTreatmentAdvanced or Metastatic HER2-negative Breast Cancer1
2Active Not RecruitingTreatmentBreast Cancer, Gastric Cancer / Tumors, Solid1
2Active Not RecruitingTreatmentCLDN18.2-positive Adenocarcinoma of Esophagus / CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction / CLDN18.2-positive Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentCancer, Breast5
2Active Not RecruitingTreatmentCancers1
2Active Not RecruitingTreatmentCarcinoma, Islet Cell / Gastrinoma / Glucagonoma / Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Somatostatinoma1
2Active Not RecruitingTreatmentColorectal Cancers2
2Active Not RecruitingTreatmentEsophageal Cancers / Gastric Cancers2
2Active Not RecruitingTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer1
2Active Not RecruitingTreatmentGastric Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
2Active Not RecruitingTreatmentGastric Adenocarcinoma / Neoplasms, Gastrointestinal1
2Active Not RecruitingTreatmentGastric Cancers5
2Active Not RecruitingTreatmentGastric cancer stage IV1
2Active Not RecruitingTreatmentGastrinoma / Glucagonoma / Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Recurrent Pancreatic Cancer / Somatostatinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentGastroesophageal Junction Neoplasms / Stomach Neoplasms1
2Active Not RecruitingTreatmentGastrointestinal Cancers1
2Active Not RecruitingTreatmentHER2/Neu Positive / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentHead and Neck Cancers / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity1
2Active Not RecruitingTreatmentHepatocellular Carcinomas1
2Active Not RecruitingTreatmentHer-2 Positive Gastric Cancer / Metastatic or Recurrent Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentLiver Metastases / Rectal Cancers1
2Active Not RecruitingTreatmentMalignant Neoplasm of Female Breast1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers3
2Active Not RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
2Active Not RecruitingTreatmentNeoplasms, Pancreatic1
2Active Not RecruitingTreatmentPancreatic Cancers6
2Active Not RecruitingTreatmentRectal Adenocarcinoma / Stage II Rectal Cancer / Stage III Rectal Cancer1
2Active Not RecruitingTreatmentRectal Cancers3
2Active Not RecruitingTreatmentRecurrent Small Intestine Cancer / Small Intestine Adenocarcinoma1
2CompletedNot AvailableMetastatic Breast Cancer (MBC)1
2CompletedTreatment70 Years Old Patients and Over / After One Line of Chemotherapy With Trastuzumab / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of Oesophagus1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Liver Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2CompletedTreatmentAdvanced or Recurrent Esophageal Squamous Cell Carcinoma1
2CompletedTreatmentAdvanced/Metastatic Breast Cancer1
2CompletedTreatmentAnal Canal Cancers1
2CompletedTreatmentAnal Cancer1
2CompletedTreatmentAnaplastic Glioma of Brain / Brain Cancer / Glioblastoma Multiforme1
2CompletedTreatmentBiliary Tract Cancer2
2CompletedTreatmentBrainstem Glioma1
2CompletedTreatmentBreast Cancer Metastatic1
2CompletedTreatmentCancer of the Biliary Tract / Cancer of the Gallbladder1
2CompletedTreatmentCancer, Breast24
2CompletedTreatmentCancer, Breast / Elderly Patients1
2CompletedTreatmentCancer, Breast / Estrogen Receptor Positive Tumor1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Tumors, Solid1
2CompletedTreatmentCancer, Breast / Metastatic Cancers1
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis2
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancers2
2CompletedTreatmentCarcinoma of the Prostate4
2CompletedTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Recurrent Cervical Carcinoma1
2CompletedTreatmentCervical Cancers2
2CompletedTreatmentCholangiocarcinomas3
2CompletedTreatmentColon Cancer3
2CompletedTreatmentColon Cancer / Colorectal Cancers1
2CompletedTreatmentColorectal Adenocarcinoma1
2CompletedTreatmentColorectal Cancers29
2CompletedTreatmentColorectal Cancers / Neoplasms Metastasis2
2CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
2CompletedTreatmentERBB2 Gene Amplification / Neoplasms Metastasis / Stomach Neoplasms1
2CompletedTreatmentEffects of Chemotherapy / Malignant Neoplasm of Stomach1
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentEsophageal Cancers / Gastric Cancers3
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer2
2CompletedTreatmentGastric Cancers12
2CompletedTreatmentGastric Carcinoma / Gastroesophageal Junction Carcinoma1
2CompletedTreatmentGastric cancer stage IV3
2CompletedTreatmentGastro Oesophageal Cancer1
2CompletedTreatmentGastrointestinal Cancers2
2CompletedTreatmentGastrointestinal Carcinoid Tumor / Islet Cell Tumor1
2CompletedTreatmentHead and Neck Cancers3
2CompletedTreatmentHead or Neck Cancer1
2CompletedTreatmentHepatocellular Carcinomas1
2CompletedTreatmentKidney Cancer2
2CompletedTreatmentKidney Cancer / Renal Cell Carcinoma (RCC)1
2CompletedTreatmentLiver Cancer2
2CompletedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentMalignant Gliomas1
2CompletedTreatmentMesothelioma, Malignant1
2CompletedTreatmentMetastatic Adenocarcinoma of the Pancreas1
2CompletedTreatmentMetastatic Breast Cancer (MBC)6
2CompletedTreatmentMetastatic Breast Cancer (MBC) / Neoplasms, Breast1
2CompletedTreatmentMetastatic Colorectal Cancers10
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentNasopharyngeal Cancers2
2CompletedTreatmentNasopharyngeal Neoplasms1
2CompletedTreatmentNeoplasms1
2CompletedTreatmentNeoplasms Metastasis / Pancreatic Cancers1
2CompletedTreatmentNeoplasms Metastasis / Stomach Neoplasms1
2CompletedTreatmentNeoplasms, Breast2
2CompletedTreatmentNeoplasms, Breast / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNeoplasms, Colorectal3
2CompletedTreatmentNeoplasms, Gastrointestinal Tract1
2CompletedTreatmentNeoplasms, Kidney1
2CompletedTreatmentNeuroendocrine Tumors2
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentOesophageal Carcinoma1
2CompletedTreatmentPancreatic Cancer Metastatic2
2CompletedTreatmentPancreatic Cancer Stage IVA1
2CompletedTreatmentPancreatic Cancers14
2CompletedTreatmentRectal Cancers8
2CompletedTreatmentRectal Neoplasms5
2CompletedTreatmentRectal Tumour1
2CompletedTreatmentRectum Cancer1
2CompletedTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentRenal Cell Carcinoma (RCC)2
2CompletedTreatmentResectable Rectal Cancer Clinical Stage II and III1
2CompletedTreatmentResected Advanced Gastric Cancer1
2CompletedTreatmentStage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2CompletedTreatmentStage IV Gastric Cancer With Metastasis1
2CompletedTreatmentStomach Neoplasms2
2CompletedTreatmentThyroid Cancers1
2CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
2CompletedTreatmentUnknown Primary Neoplasms1
2Enrolling by InvitationTreatmentBreastcancer / Colorectal Cancers / Lung Cancer Non-Small Cell / Pancreatic Cancers1
2Not Yet RecruitingTreatmentBiliary Tract Cancer1
2Not Yet RecruitingTreatmentBiliary Tract Cancer / Capecitabine / Chemotherapy, Adjuvant / Cholangiocarcinomas / Cisplatin / Gemcitabine1
2Not Yet RecruitingTreatmentBiliary Tract Neoplasms1
2Not Yet RecruitingTreatmentCancer, Breast2
2Not Yet RecruitingTreatmentCapecitabine / Neuroendocrine Carcinomas / Neuroendocrine Tumors / Temozolomide1
2Not Yet RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2Not Yet RecruitingTreatmentGastric Cancers2
2Not Yet RecruitingTreatmentGastric cancer stage IV1
2Not Yet RecruitingTreatmentHepatocellular Carcinomas1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Colorectum1
2Not Yet RecruitingTreatmentRectal Adenocarcinoma1
2Not Yet RecruitingTreatmentRecurrent Colorectal Carcinoma / Stage IV Colorectal Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
2Not Yet RecruitingTreatmentStage II Breast Cancer / Stage III Breast Cancer1
2RecruitingNot AvailableCancers1
2RecruitingNot AvailableMetastatic Pancreatic Adenocarcinoma1
2RecruitingNot AvailableRectal Cancers1
2RecruitingTreatmentAdenocarcinoma of the Gastro-oesophageal Junction / Adenocarcinoma of the Oesophagus / Adenocarcinoma of the Stomach1
2RecruitingTreatmentAdenocarcinoma of the Pancreas1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Carcinoma / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Gastric Cancers1
2RecruitingTreatmentAdenocarcinomas / Carcinomas / Rectal Neoplasms1
2RecruitingTreatmentAnal Basaloid Carcinoma / Anal Canal Cloacogenic Carcinoma / Anal Squamous Cell Carcinoma / Metastatic Anal Canal Carcinoma / Recurrent Anal Canal Carcinoma / Stage IIIB Anal Canal Cancer / Stage IV Anal Canal Cancer1
2RecruitingTreatmentBiliary Tract Cancer1
2RecruitingTreatmentCancer, Breast5
2RecruitingTreatmentCancer, Breast / Gastrointestinal Cancers1
2RecruitingTreatmentCancer, Breast / Metastases, Brain / Metastatic Breast Cancer (MBC) / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentColon Cancer1
2RecruitingTreatmentColon Cancer / Esophagus Cancer / Rectum Cancer / Small Bowel Cancer / Stomach Cancer1
2RecruitingTreatmentColorectal Cancer Liver Metastases1
2RecruitingTreatmentColorectal Cancers4
2RecruitingTreatmentColorectal Large Cell Neuroendocrine Carcinoma / Esophageal Large Cell Neuroendocrine Carcinoma / Gallbladder Large Cell Neuroendocrine Carcinoma / Gastric Large Cell Neuroendocrine Carcinoma / Pancreatic Large Cell Neuroendocrine Carcinoma / Small Intestinal Large Cell Neuroendocrine Carcinoma1
2RecruitingTreatmentEsophageal Cancers / Gastric Cancers1
2RecruitingTreatmentGastric Adenocarcinoma / Gastroesophageal-junction Adenocarcinoma1
2RecruitingTreatmentGastric Cancers2
2RecruitingTreatmentGastric Cancers / Gastroesophageal Junction Cancer1
2RecruitingTreatmentGastro-entero-pancreatic Neuroendocrine Tumors1
2RecruitingTreatmentHER2 Positive Breast Cancers2
2RecruitingTreatmentHER2-positive Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2RecruitingTreatmentHepatocellular Carcinomas / Secondary1
2RecruitingTreatmentLocally Advanced Colorectal Cancer1
2RecruitingTreatmentMalignant Tumor of the Breast / Neoplasms, Breast1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)3
2RecruitingTreatmentMetastatic Colorectal Cancers3
2RecruitingTreatmentMetastatic gpNMB Over-expressing Triple Negative Breast Cancer1
2RecruitingTreatmentMidgut Neuroendocrine Tumours / Pancreatic Neuroendocrine Tumors (pNET)1
2RecruitingTreatmentNasopharyngeal Neoplasms1
2RecruitingTreatmentNeoplasms, Colorectal3
2RecruitingTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2RecruitingTreatmentPancreatic Cancers2
2RecruitingTreatmentPancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentPancreatic Ductal Carcinoma / Resectable Pancreatic Cancers1
2RecruitingTreatmentRectal Adenocarcinoma1
2RecruitingTreatmentRectal Adenocarcinoma / Stage II Rectal Cancer / Stage III Rectal Cancer1
2RecruitingTreatmentRectal Cancers5
2RecruitingTreatmentRectal Carcinoma1
2RecruitingTreatmentSquamous Cell Carcinoma (SCC) / Squamous Cell Carcinoma of Skin1
2RecruitingTreatmentUnresectable Pancreatic Cancer1
2SuspendedTreatmentGastric Cancers2
2SuspendedTreatmentRecurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedNot AvailableCarcinoma of Unknown Primary1
2TerminatedDiagnosticHead and Neck Cancers1
2TerminatedTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer1
2TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Cancers1
2TerminatedTreatmentAdenocarcinomas / Colon Cancer1
2TerminatedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2TerminatedTreatmentAdvanced Breast Cancer / Cancer, Breast / HER2/Neu-positive Breast Cancer / Metastatic Breast Cancer (MBC)1
2TerminatedTreatmentBile Duct Cancer / Cancer of Gallbladder / Cholangiocarcinomas / Hepatobiliary Neoplasms / Liver Cancer1
2TerminatedTreatmentBiliary Cancer1
2TerminatedTreatmentBreast Cancer, Metastatic / Cancer treatment1
2TerminatedTreatmentCancer, Breast11
2TerminatedTreatmentCancer, Breast / Metastatic Cancers1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentCancers1
2TerminatedTreatmentCarcinoma of Anal Canal1
2TerminatedTreatmentColorectal Cancers7
2TerminatedTreatmentColorectal Cancers / Metastases1
2TerminatedTreatmentColorectal Cancers / Neoplasms Metastasis1
2TerminatedTreatmentDrug Therapy, Combination / Neoplasms, Colorectal / Secondary1
2TerminatedTreatmentEsophageal Cancers / Gastric Adenocarcinoma / Gastric Cancers1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage I Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2TerminatedTreatmentGastric Adenocarcinoma1
2TerminatedTreatmentGastric Cancers1
2TerminatedTreatmentGastroEsophageal Cancer1
2TerminatedTreatmentHead and Neck Cancers1
2TerminatedTreatmentHepatocellular Cancer / Liver Cancer1
2TerminatedTreatmentHepatocellular Carcinomas2
2TerminatedTreatmentInvasive Breast Carcinoma / Primary Invasive Breast Cancer / Stage I Breast Cancer / Stage II Breast Cancer / Stage III Breast Cancer1
2TerminatedTreatmentKRAS Wild Type / Resectable Type II Gastric Adenocarcinoma1
2TerminatedTreatmentLiver Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)2
2TerminatedTreatmentMetastatic Colorectal Cancers5
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentNeoplasms, Breast / Relapsed Breast Cancer1
2TerminatedTreatmentNeoplasms, Colorectal4
2TerminatedTreatmentNeoplasms, Pancreatic1
2TerminatedTreatmentPancreas Cancer1
2TerminatedTreatmentPancreatic Cancers2
2TerminatedTreatmentRectal Cancers3
2TerminatedTreatmentRecurrent Skin Cancer / Squamous Cell Carcinoma of the Skin1
2TerminatedTreatmentTriple Negative Metastatic Breast Cancer1
2Unknown StatusTreatmentAdenocarcinoma Clear Cell1
2Unknown StatusTreatmentAdvanced Breast Cancer1
2Unknown StatusTreatmentAdvanced Colorectal Cancer1
2Unknown StatusTreatmentBiliary Tract Cancer / Gallbladder Adenocarcinoma1
2Unknown StatusTreatmentBone Metastases / Tumors, Solid1
2Unknown StatusTreatmentCancer, Breast5
2Unknown StatusTreatmentCancer, Breast / Metastasis2
2Unknown StatusTreatmentCholangiocarcinomas1
2Unknown StatusTreatmentColorectal Adenocarcinoma1
2Unknown StatusTreatmentColorectal Cancers9
2Unknown StatusTreatmentEsophageal Cancers1
2Unknown StatusTreatmentEsophageal Cancers / Gastric Cancers1
2Unknown StatusTreatmentGastric (Stomach) Cancer / Gastrointestinal Stromal Tumors (GISTs) / Neoplasm of Cardioesophageal Junction / Stomach Cancer1
2Unknown StatusTreatmentGastric Cancers4
2Unknown StatusTreatmentGastric Carcinoma1
2Unknown StatusTreatmentGastrointestinal Cancers1
2Unknown StatusTreatmentHead and Neck Cancers1
2Unknown StatusTreatmentLiver Metastases / Metastatic Breast Cancer (MBC)2
2Unknown StatusTreatmentLocally Advanced Non-resectable Breast Cancer / Metastatic Breast Cancer (MBC)1
2Unknown StatusTreatmentLocally Advanced Rectal Cancer2
2Unknown StatusTreatmentLung Cancers1
2Unknown StatusTreatmentMetastatic Breast Cancer (MBC)2
2Unknown StatusTreatmentMetastatic Colorectal Cancers2
2Unknown StatusTreatmentNeoadjuvant Therapy / Rectal Neoplasms1
2Unknown StatusTreatmentNeoadjuvant Treatment / Rectal Neoplasms1
2Unknown StatusTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2Unknown StatusTreatmentNeoplasms Metastasis / Rectal Cancers1
2Unknown StatusTreatmentNeoplasms, Breast1
2Unknown StatusTreatmentNeoplasms, Colorectal1
2Unknown StatusTreatmentNeoplasms, Colorectal / Neoplasms, Liver1
2Unknown StatusTreatmentNeuroendocrine Carcinomas1
2Unknown StatusTreatmentOesophageal Cancer1
2Unknown StatusTreatmentPancreatic Cancer Metastatic1
2Unknown StatusTreatmentPancreatic Cancers2
2Unknown StatusTreatmentParanasal Sinus Squamous Cell Carcinoma / Recurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Oral Cavity Squamous Cell Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Hypopharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Oral Cavity Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma1
2Unknown StatusTreatmentRectal Cancers3
2Unknown StatusTreatmentStage T3-4NxM0 Gastric Cancer1
2Unknown StatusTreatmentStomach Cancer1
2Unknown StatusTreatmentStomach Neoplasms3
2WithdrawnTreatmentBiliary Tract Cancer1
2WithdrawnTreatmentCancer, Breast2
2WithdrawnTreatmentCarcinoma of Unknown Primary1
2WithdrawnTreatmentColorectal Cancers1
2WithdrawnTreatmentColorectal Cancers / Metastatic Cancers2
2WithdrawnTreatmentMetastatic Colorectal Cancers4
2WithdrawnTreatmentRectal Cancers / Rectal Neoplasms1
2WithdrawnTreatmentRecurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity1
2, 3Active Not RecruitingTreatmentPancreatic Cancers1
2, 3CompletedTreatmentCancer, Breast1
2, 3CompletedTreatmentPancreatic Cancers1
2, 3Not Yet RecruitingTreatmentBiliary Tract Cancer1
2, 3Not Yet RecruitingTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal / Peritoneal Diseases / Peritoneal Neoplasms1
2, 3RecruitingTreatmentCancer, Breast1
2, 3RecruitingTreatmentColorectal Cancers1
2, 3RecruitingTreatmentGastric Cancers2
2, 3RecruitingTreatmentGastroesophageal Junction Adenocarcinoma1
2, 3RecruitingTreatmentOesophageal Cancer1
2, 3RecruitingTreatmentOesophagogastric Cancer1
2, 3RecruitingTreatmentPancreatic Cancers1
2, 3RecruitingTreatmentRectal Cancers1
2, 3TerminatedTreatmentCancer, Breast2
2, 3TerminatedTreatmentCancer, Breast / HER2 Positive Breast Cancers1
2, 3Unknown StatusDiagnosticColorectal Cancers1
2, 3Unknown StatusTreatmentC04.588.274.476.411.3071
2, 3Unknown StatusTreatmentCancer, Breast2
2, 3Unknown StatusTreatmentColorectal Cancers1
2, 3Unknown StatusTreatmentEsophageal Cancers1
2, 3Unknown StatusTreatmentHepatocellular Carcinomas / Neoplasms Metastasis1
2, 3Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
2, 3Unknown StatusTreatmentPancreatic Cancer Stage II / Pancreatic Cancer Stage III1
2, 3Unknown StatusTreatmentRectal Cancers1
3Active Not RecruitingTreatmentBorderline Ovarian Mucinous Tumor / Ovarian Mucinous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Stage IA Fallopian Tube Cancer / Stage IA Ovarian Cancer / Stage IB Fallopian Tube Cancer / Stage IB Ovarian Cancer / Stage IC Fallopian Tube Cancer / Stage IC Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer1
3Active Not RecruitingTreatmentCRC1
3Active Not RecruitingTreatmentCancer, Breast8
3Active Not RecruitingTreatmentCognitive/Functional Effects / Colorectal Cancers / Neurotoxicity1
3Active Not RecruitingTreatmentColorectal Cancers3
3Active Not RecruitingTreatmentColorectal Cancers / Metastases1
3Active Not RecruitingTreatmentDigestive System Neoplasms / Intestinal Neoplasms / Neoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Gastrointestinal1
3Active Not RecruitingTreatmentGastric Cancers2
3Active Not RecruitingTreatmentGastroesophageal Junction Adenocarcinoma / Metastatic Gastric Adenocarcinoma1
3Active Not RecruitingTreatmentLocally Advanced Malignant Neoplasm / Pancreatic Cancers / Pancreatic Carcinoma Non-resectable1
3Active Not RecruitingTreatmentMalignant Neoplasm of Breast1
3Active Not RecruitingTreatmentMetastases, Brain1
3Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)2
3Active Not RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
3Active Not RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
3Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
3Active Not RecruitingTreatmentNeoplasms, Gastrointestinal Tract1
3CompletedTreatmentAdenocarcinomas1
3CompletedTreatmentAdvanced Colorectal Cancer1
3CompletedTreatmentAdverse Drug Events / Complications / Hospital Costs / Length of Stay / Quality of Life1
3CompletedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
3CompletedTreatmentCancer, Breast20
3CompletedTreatmentCancer, Breast / Cancers1
3CompletedTreatmentCancer, Breast / Metastases2
3CompletedTreatmentColorectal Cancers18
3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
3CompletedTreatmentGastric Cancers5
3CompletedTreatmentGastric Cancers / General Surgery1
3CompletedTreatmentMetastatic Breast Cancer (MBC)3
3CompletedTreatmentMetastatic Colorectal Cancers1
3CompletedTreatmentNeoplasms, Breast2
3CompletedTreatmentNeoplasms, Pancreatic1
3CompletedTreatmentPancreatic Cancers4
3CompletedTreatmentRectal Cancers1
3CompletedTreatmentStomach Neoplasms1
3Not Yet RecruitingPreventionColon Cancer / Intraperitoneal Rectal Cancer1
3Not Yet RecruitingTreatmentAnus Diseases / Anus Neoplasms / Carcinomas / Neoplasms / Neoplasms, Squamous Cell / Squamous Cell Carcinoma (SCC)1
3Not Yet RecruitingTreatmentCancer, Breast3
3Not Yet RecruitingTreatmentNasopharyngeal Carcinoma2
3Not Yet RecruitingTreatmentRectal Cancers1
3RecruitingPreventionChemotherapy-Induced Neutropenia / Colorectal Cancers1
3RecruitingPreventionCholangiocarcinomas1
3RecruitingSupportive CareRectal Cancers1
3RecruitingTreatmentAdvanced Rectal Cancer1
3RecruitingTreatmentBreast Cancer Model / Cancer, Breast / Effects of Chemotherapy1
3RecruitingTreatmentBreast Diseases / Neoplasms by Site / Neoplasms Metastasis / Neoplasms, Breast / Skin Diseases1
3RecruitingTreatmentBreast Neoplasm Female1
3RecruitingTreatmentCancer of the Rectum1
3RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentColon Cancer2
3RecruitingTreatmentEffects of Chemotherapy / Effects of Radiation Therapy / General Surgery / Neoplasms, Colorectal1
3RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Invasive Breast Carcinoma / Progesterone Receptor Negative / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Carcinoma1
3RecruitingTreatmentGastric Adenocarcinoma1
3RecruitingTreatmentGastric Cancer, Adjuvant Chemotherapy, XO1
3RecruitingTreatmentGastric Cancers5
3RecruitingTreatmentGastric Cancers / Gastroesophageal Junction Cancer1
3RecruitingTreatmentGastric cancer stage IV1
3RecruitingTreatmentHER-2 Positive Breast Cancer / Neoplasms, Metastatic1
3RecruitingTreatmentHER2 Positive Metastatic Breast Cancers1
3RecruitingTreatmentHER2+ Metastatic Breast Cancer (MBC)1
3RecruitingTreatmentHER2-positive Locally Advanced or Metastatic Breast Cancer1
3RecruitingTreatmentLocally Advanced Rectal Cancer1
3RecruitingTreatmentLocally Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
3RecruitingTreatmentMalignant Neoplasm Other Gallbladder/Extrahepatic Bile Duct1
3RecruitingTreatmentMetastatic Breast Cancer (MBC)2
3RecruitingTreatmentMetastatic Colorectal Cancers1
3RecruitingTreatmentNasopharyngeal Carcinoma3
3RecruitingTreatmentNeoplasms, Colorectal1
3RecruitingTreatmentNeoplasms, Esophageal / Stage III Esophageal Squamous Cell Carcinoma1
3RecruitingTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Pancreatic Intraductal Papillary-Mucinous Neoplasm / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
3RecruitingTreatmentPancreatic Cancers1
3RecruitingTreatmentRectal Cancers1
3RecruitingTreatmentRectal Carcinoma1
3RecruitingTreatmentRectal Neoplasms2
3RecruitingTreatmentStage II Esophageal Squamous Cell Carcinoma / Stage III Esophageal Squamous Cell Carcinoma2
3RecruitingTreatmentStomach Neoplasms2
3RecruitingTreatmentUnresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction1
3TerminatedSupportive CareCancer, Breast / Colorectal Cancers / Pain1
3TerminatedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
3TerminatedTreatmentCancer, Breast2
3TerminatedTreatmentColorectal Cancers / Liver Metastases1
3TerminatedTreatmentColorectal Cancers / Metastatic Cancers1
3TerminatedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
3TerminatedTreatmentGastric Cancers3
3TerminatedTreatmentGastric Carcinoma Stage IV1
3TerminatedTreatmentMetastatic Breast Cancer (MBC)1
3TerminatedTreatmentMetastatic Pancreatic Adenocarcinoma That is Recurrent1
3TerminatedTreatmentMucinous Adenocarcinoma of the Rectum / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer / Stage IVA Rectal Cancer / Stage IVB Rectal Cancer1
3TerminatedTreatmentNeoplasms, Breast1
3TerminatedTreatmentOesophago-gastric Cancer1
3TerminatedTreatmentRenal Cell Cancer1
3Unknown StatusTreatmentCancer, Breast1
3Unknown StatusTreatmentColorectal Cancers6
3Unknown StatusTreatmentColorectal Cancers / Metastatic Cancers1
3Unknown StatusTreatmentColorectal Cancers / Resectable Liver Metastasis1
3Unknown StatusTreatmentGastric Cancers2
3Unknown StatusTreatmentLiver Metastases / Neoplasms, Colorectal1
3Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
3Unknown StatusTreatmentMetastatic Colorectal Cancers3
3Unknown StatusTreatmentPancreatic Cancers1
3WithdrawnTreatmentHepatic neoplasms malignant1
4Approved for MarketingNot AvailableNeoplasms, Breast1
4CompletedBasic ScienceAdenocarcinoma of the Pancreas1
4CompletedDiagnosticCancer, Breast / Colorectal Cancers1
4CompletedTreatmentCancer, Breast2
4CompletedTreatmentColorectal Cancers5
4CompletedTreatmentUpper Gastrointestinal Tumours1
4RecruitingNot AvailableBreast Cancer Recurrent / HER2/Neu-negative Carcinoma of Breast / Hormone Receptor Positive Malignant Neoplasm of Breast1
4TerminatedBasic ScienceAdenocarcinoma of the Stomach1
4TerminatedTreatmentCancer, Breast1
4TerminatedTreatmentColorectal Cancers1
4Unknown StatusTreatmentGastric Cancers / Liver Metastasis1
Not AvailableActive Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
Not AvailableActive Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedNot AvailableBreast Cancer, Colorectal Cancer, Gastric Cancer1
Not AvailableCompletedNot AvailableCancer, Breast3
Not AvailableCompletedNot AvailableCancer, Breast / Metastatic Cancers1
Not AvailableCompletedNot AvailableColon Cancer / Metastatic Breast Cancer (MBC) / Metastatic Breast Cancer, Colon Cancer1
Not AvailableCompletedNot AvailableColorectal Cancers3
Not AvailableCompletedSupportive CareExtrahepatic Bile Duct Cancer / Nausea / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Vomiting1
Not AvailableCompletedTreatmentCancer, Breast2
Not AvailableCompletedTreatmentCancer, Breast / Stage I Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedTreatmentCancers / Colonic Diseases1
Not AvailableCompletedTreatmentMetastatic Colorectal Cancers1
Not AvailableNot Yet RecruitingNot AvailableCancer of Lymph Node / Stomach Neoplasms1
Not AvailableNot Yet RecruitingTreatmentNeoadjuvant Chemoradiation / Rectal Cancer, Adenocarcinoma1
Not AvailableRecruitingNot AvailableCancer, Breast1
Not AvailableRecruitingNot AvailableColorectal Cancers1
Not AvailableRecruitingNot AvailableMetastatic Gastric Cancers1
Not AvailableRecruitingBasic ScienceBMI >30 kg/m2 / Neoplasms1
Not AvailableRecruitingTreatmentAdenocarcinomas1
Not AvailableRecruitingTreatmentCancer, Breast2
Not AvailableRecruitingTreatmentEsophageal Cancers / Gastric Cancers1
Not AvailableRecruitingTreatmentNeoplasms1
Not AvailableRecruitingTreatmentRectal Cancers1
Not AvailableRecruitingTreatmentRecurrent Rectal Cancer1
Not AvailableTerminatedNot AvailableCancer, Breast1
Not AvailableTerminatedTreatmentEsophageal Adenocarcinomas1
Not AvailableTerminatedTreatmentPancreatic Cancers2
Not AvailableUnknown StatusNot AvailableRectal Cancers1
Not AvailableUnknown StatusTreatmentHilar Cholangiocarcinoma / Primary Sclerosing Cholangitis (PSC)1
Not AvailableUnknown StatusTreatmentMetastatic Colorectal Cancers1
Not AvailableUnknown StatusTreatmentNasopharyngeal Neoplasms1
Not AvailableWithdrawnTreatmentPancreatic Cancers1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral150 mg/1
TabletOral500 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral150 mg
Tablet, film coatedOral300 mg
Tablet, film coatedOral500 mg
TabletOral150 mg
TabletOral500 mg
Prices
Unit descriptionCostUnit
Xeloda 500 mg tablet28.97USD tablet
Xeloda 150 mg tablet8.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1327358 No1994-03-012011-03-01Canada
CA2103324 No1997-12-232013-11-17Canada
US4966891 No1994-01-132011-01-13Us
US5472949 No1993-12-142013-12-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point110-121 °CNot Available
water solubility26 mg/mLNot Available
logP0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.248 mg/mLALOGPS
logP1.17ALOGPS
logP0.77ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)8.23ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area120.69 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity82.75 m3·mol-1ChemAxon
Polarizability35.81 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9513
Blood Brain Barrier+0.6064
Caco-2 permeable-0.7096
P-glycoprotein substrateSubstrate0.5106
P-glycoprotein inhibitor INon-inhibitor0.8234
P-glycoprotein inhibitor IINon-inhibitor0.7514
Renal organic cation transporterNon-inhibitor0.9654
CYP450 2C9 substrateNon-substrate0.7999
CYP450 2D6 substrateNon-substrate0.864
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.7523
CYP450 2C9 inhibitorNon-inhibitor0.7673
CYP450 2D6 inhibitorNon-inhibitor0.8612
CYP450 2C19 inhibitorNon-inhibitor0.6569
CYP450 3A4 inhibitorNon-inhibitor0.7404
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8484
Ames testNon AMES toxic0.6521
CarcinogenicityNon-carcinogens0.8754
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.4690 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9759
hERG inhibition (predictor II)Non-inhibitor0.7124
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives.
KingdomChemical entities
Super ClassOrganic compounds
ClassNucleosides, nucleotides, and analogues
Sub Class5'-deoxyribonucleosides
Direct Parent5'-deoxyribonucleosides
Alternative Parents
Substituents
  • 5'-deoxyribonucleoside
  • Glycosyl compound
  • N-glycosyl compound
  • Halopyrimidine
  • Pyrimidone
  • Aryl fluoride
  • Aryl halide
  • Hydropyrimidine
  • Pyrimidine
  • Heteroaromatic compound
  • Oxolane
  • 1,2-diol
  • Secondary alcohol
  • Organoheterocyclic compound
  • Oxacycle
  • Azacycle
  • Carboximidic acid derivative
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organohalogen compound
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organofluoride
  • Organonitrogen compound
  • Organooxygen compound
  • Alcohol
  • Hydrocarbon derivative
  • Organic oxide
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thymidylate synthase activity
Specific Function:
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:
TYMS
Uniprot ID:
P04818
Molecular Weight:
35715.65 Da
References
  1. Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL: Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol. 2004 May;53(5):409-14. [PubMed:15132128 ]
  2. Eliason JF, Megyeri A: Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets. 2004 May;5(4):383-8. [PubMed:15134221 ]
  3. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. [PubMed:15709193 ]
  4. Li KM, Rivory LP, Clarke SJ: Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 5;820(1):121-30. Epub 2005 Apr 19. [PubMed:15866500 ]
  5. Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G: Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. Anticancer Drugs. 2006 Aug;17(7):807-13. [PubMed:16926630 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
2. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
incorporation into and destabilization
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Walko CM, Lindley C: Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. [PubMed:15763604 ]
  2. Thomas DM, Zalcberg JR: 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 1998 Nov;25(11):887-95. [PubMed:9807659 ]
  3. Wyatt MD, Wilson DM 3rd: Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009 Mar;66(5):788-99. doi: 10.1007/s00018-008-8557-5. [PubMed:18979208 ]
  4. Ghoshal K, Jacob ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 1997 Jun 1;53(11):1569-75. [PubMed:9264308 ]
  5. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. [PubMed:12724731 ]
  6. Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. [PubMed:15032669 ]
3. RNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
incorporation into and destabilization
References
  1. Walko CM, Lindley C: Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. [PubMed:15763604 ]
  2. Thomas DM, Zalcberg JR: 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 1998 Nov;25(11):887-95. [PubMed:9807659 ]
  3. Wyatt MD, Wilson DM 3rd: Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009 Mar;66(5):788-99. doi: 10.1007/s00018-008-8557-5. [PubMed:18979208 ]
  4. Ghoshal K, Jacob ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 1997 Jun 1;53(11):1569-75. [PubMed:9264308 ]
  5. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. [PubMed:12724731 ]
  6. Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. [PubMed:15032669 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transferase activity, transferring pentosyl groups
Specific Function:
May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro.Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.
Gene Name:
TYMP
Uniprot ID:
P19971
Molecular Weight:
49954.965 Da
References
  1. de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs. 2001;19(1):41-59. [PubMed:11291832 ]
  2. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y: A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001 Aug;18(8):1190-202. [PubMed:11587492 ]
  3. Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR: Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45. [PubMed:12481438 ]
  4. Ishitsuka H, Shimma N, Horii I: [Discovery and development of novel anticancer drug capecitabine]. Yakugaku Zasshi. 1999 Dec;119(12):881-97. [PubMed:10630095 ]
  5. Ishitsuka H: Capecitabine: preclinical pharmacology studies. Invest New Drugs. 2000 Nov;18(4):343-54. [PubMed:11081570 ]
  6. Endo M, Miwa M, Eda H, Ura M, Tanimura H, Ishikawa T, Miyazaki-Nose T, Hattori K, Shimma N, Yamada-Okabe H, Ishitsuka H: Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805. [PubMed:12866042 ]
  7. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291-7. [PubMed:10755317 ]
  8. Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL: Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol. 2004 May;53(5):409-14. [PubMed:15132128 ]
  9. Eliason JF, Megyeri A: Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets. 2004 May;5(4):383-8. [PubMed:15134221 ]
  10. Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G: Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. Anticancer Drugs. 2006 Aug;17(7):807-13. [PubMed:16926630 ]
  11. Walko CM, Lindley C: Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. [PubMed:15763604 ]
  12. Ranieri G, Roccaro AM, Vacca A, Ribatti D: Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside. Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):171-83. [PubMed:18221035 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs. 2001;19(1):41-59. [PubMed:11291832 ]
  2. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y: A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001 Aug;18(8):1190-202. [PubMed:11587492 ]
  3. Ishitsuka H, Shimma N, Horii I: [Discovery and development of novel anticancer drug capecitabine]. Yakugaku Zasshi. 1999 Dec;119(12):881-97. [PubMed:10630095 ]
  4. Ishitsuka H: Capecitabine: preclinical pharmacology studies. Invest New Drugs. 2000 Nov;18(4):343-54. [PubMed:11081570 ]
  5. Endo M, Miwa M, Eda H, Ura M, Tanimura H, Ishikawa T, Miyazaki-Nose T, Hattori K, Shimma N, Yamada-Okabe H, Ishitsuka H: Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805. [PubMed:12866042 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
Gene Name:
DPYD
Uniprot ID:
Q12882
Molecular Weight:
111400.32 Da
References
  1. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y: A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001 Aug;18(8):1190-202. [PubMed:11587492 ]
  2. Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR: Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45. [PubMed:12481438 ]
  3. de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs. 2001;19(1):41-59. [PubMed:11291832 ]
  4. Gross E, Seck K, Neubauer S, Mayr J, Hellebrand H, Ratanaphan A, Lutz V, Stockinger H, Kiechle M: High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int J Oncol. 2003 Feb;22(2):325-32. [PubMed:12527930 ]
  5. Ishitsuka H: Capecitabine: preclinical pharmacology studies. Invest New Drugs. 2000 Nov;18(4):343-54. [PubMed:11081570 ]
  6. Endo M, Miwa M, Eda H, Ura M, Tanimura H, Ishikawa T, Miyazaki-Nose T, Hattori K, Shimma N, Yamada-Okabe H, Ishitsuka H: Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805. [PubMed:12866042 ]
  7. Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL: Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol. 2004 May;53(5):409-14. [PubMed:15132128 ]
  8. Eliason JF, Megyeri A: Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets. 2004 May;5(4):383-8. [PubMed:15134221 ]
  9. Walko CM, Lindley C: Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. [PubMed:15763604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
Gene Name:
CDA
Uniprot ID:
P32320
Molecular Weight:
16184.545 Da
References
  1. de Bono JS, Twelves CJ: The oral fluorinated pyrimidines. Invest New Drugs. 2001;19(1):41-59. [PubMed:11291832 ]
  2. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y: A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001 Aug;18(8):1190-202. [PubMed:11587492 ]
  3. Ishitsuka H, Shimma N, Horii I: [Discovery and development of novel anticancer drug capecitabine]. Yakugaku Zasshi. 1999 Dec;119(12):881-97. [PubMed:10630095 ]
  4. Ishitsuka H: Capecitabine: preclinical pharmacology studies. Invest New Drugs. 2000 Nov;18(4):343-54. [PubMed:11081570 ]
  5. Endo M, Miwa M, Eda H, Ura M, Tanimura H, Ishikawa T, Miyazaki-Nose T, Hattori K, Shimma N, Yamada-Okabe H, Ishitsuka H: Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805. [PubMed:12866042 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 21, 2017 11:03